
|Slideshows|June 28, 2018
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Author(s)Kenneth J. Bender, PharmD, MA
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for 2026-27 Season
2
Intensive Blood Pressure Control in Primary Care May Lower Dementia Risk
3
Independent Review Supports Respiratory Virus Immunizations for 2026-27 Season
4
Diagnosing PMOS in Adolescents: Criteria, Ultrasound Limits, and Red Flags
5


























































































































